{ "schemaVersion": 1, "organisationId": "O-bbf4839684d4478487be8437b363a8cf", "slug": "jiangsu-hengrui-pharmaceut-a", "name": "JIANGSU HENGRUI PHARMACEUT-A", "updatedAt": "2026-09-28T15:27:41.796393Z", "sections": [ { "type": "OVERVIEW", "text": "Jiangsu Hengrui Pharmaceuticals is a China-based pharmaceutical company engaged in drug research and development, manufacturing, and sales. Its portfolio spans oncology, anesthesia and pain management, and metabolic and cardiovascular medicine. The company describes its approach as patient-oriented, with the aim of helping patients benefit from pharmaceutical innovation. [P132643975][P132642876][P132642970][P132642962][P132642859]\n\nChina is its principal commercial market: its sales network covered more than 25,000 hospitals and 200,000 offline pharmacies across over 30 provincial-level regions at the end of 2025. It also sells medicines and active pharmaceutical ingredients in overseas markets, including the United States and Europe, and pursues international licensing and collaborations. Established in 1997, the company reported revenue of RMB31.6 billion for 2025. [P132642948][P132643054][P132643971][P132642870]\n[P132643975][P132642876][P132642970][P132642962][P132642859][P132642948][P132643054][P132643971][P132642870]", "updatedAt": "2026-09-28T15:27:41.796393Z" }, { "type": "PRODUCTS", "text": "Jiangsu Hengrui Pharmaceuticals’ oncology products include camrelizumab, a PD-1 antibody used for several cancers including hepatocellular and lung cancer; apatinib, a VEGFR-targeting small molecule used for advanced gastric and liver cancer; and pyrotinib, an EGFR/HER2/HER4 inhibitor used for HER2-positive breast cancer. Its portfolio also includes fuzuloparib, a PARP inhibitor, and trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate. [T15215019][T15215018]\n\nOutside oncology, its products include the diabetes treatments retagliptin and retagliptin/metformin; recaticimab, a PCSK9 antibody for cholesterol reduction; and the immunology treatments ivarmacitinib, a JAK1 inhibitor, and vunakizumab, an IL-17A antibody. It also markets medicines for anesthesia and sedation, including remimazolam, and for postoperative pain, including tegileridine. The company reports pharmaceutical research and development, manufacturing and sales as one operating segment rather than a separate services business. Innovative drugs accounted for 58.3% of total drug sales in 2025; that figure is not a share for any individual product. [T15215020][T15215022][T15215023][P132644303][P132642854]\n[T15215019][T15215018][T15215020][T15215022][T15215023][P132644303][P132642854]", "updatedAt": "2026-09-28T15:27:41.796393Z" }, { "type": "GEOGRAPHY", "text": "Jiangsu Hengrui Pharmaceutical is headquartered in Lianyungang, Jiangsu, China. It reports 12 production sites across nine Chinese cities: Beijing, Tianjin, Jinan, Lianyungang, Suzhou, Shanghai, Xiamen, Chengdu and Guangzhou. Its research and development network comprises 15 centers, including four overseas centers in the United States, Europe and Australia. [P132642801][P132645276][P132644949]\n\nIn China, its sales network covers more than 30 provincial-level regions, with access to over 25,000 hospitals and 200,000 offline pharmacies. The company also reports sales of drugs and active pharmaceutical ingredients in overseas markets, including the United States and Europe. [P132642948][P132643054]\n[P132642801][P132645276][P132644949][P132642948][P132643054]", "updatedAt": "2026-09-28T15:27:41.796393Z" }, { "type": "SEGMENTS", "text": "Jiangsu Hengrui reports one operating segment: the research and development, manufacture and sale of pharmaceutical products. It does not report separate operating segments for therapeutic areas or drug types. [P132644303]\n\nAs a product-mix measure rather than a segment breakdown, innovative drugs accounted for 58.3% of drug sales in 2025. Anti-tumor products contributed approximately 81% of innovative-drug sales, with non-oncology products contributing approximately 19%. [P132642876][P132642877] By customer location, approximately 85% of total revenue came from mainland China and 15% from other countries and regions. These are geographical revenue categories, not separate operating segments. [T15215065]\n[P132644303][P132642876][P132642877][T15215065][T15215065][T15215065]", "updatedAt": "2026-09-28T15:27:41.796393Z" }, { "type": "HISTORY", "text": "Jiangsu Hengrui Pharmaceuticals traces its origins to Lianyungang Pharmaceutical Factory, where Sun Piaoyang served as factory director. The company was established as a joint-stock company on April 28, 1997, with Sun as chairman, and listed on the Shanghai Stock Exchange on October 18, 2000. [P132643769][P132643971]\n\nIts development of proprietary medicines produced several milestones: apatinib was first approved in 2014, followed by pyrotinib in 2018 and camrelizumab in 2019. Sun returned as chairman in August 2021 after stepping down in January 2020. The company added a Hong Kong Stock Exchange listing in May 2025. [T15215019][P132643769][P132643971]\n[P132643769][P132643971][T15215019][T15215019][T15215019]", "updatedAt": "2026-09-28T15:27:41.796393Z" } ], "sources": [ { "id": "P132643975", "href": "https://app.finbar.com/go?id=P132643975", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p117", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 117 }, { "id": "P132642876", "href": "https://app.finbar.com/go?id=P132642876", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p12", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 12 }, { "id": "P132642970", "href": "https://app.finbar.com/go?id=P132642970", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p26", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 26 }, { "id": "P132642962", "href": "https://app.finbar.com/go?id=P132642962", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p25", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 25 }, { "id": "P132642859", "href": "https://app.finbar.com/go?id=P132642859", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p10", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 10 }, { "id": "P132642948", "href": "https://app.finbar.com/go?id=P132642948", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p23", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 23 }, { "id": "P132643054", "href": "https://app.finbar.com/go?id=P132643054", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p37", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 37 }, { "id": "P132643971", "href": "https://app.finbar.com/go?id=P132643971", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p117", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 117 }, { "id": "P132642870", "href": "https://app.finbar.com/go?id=P132642870", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p11", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 11 }, { "id": "T15215019", "href": "https://app.finbar.com/go?id=T15215019", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p25", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 25 }, { "id": "T15215018", "href": "https://app.finbar.com/go?id=T15215018", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p24", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 24 }, { "id": "T15215020", "href": "https://app.finbar.com/go?id=T15215020", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p25", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 25 }, { "id": "T15215022", "href": "https://app.finbar.com/go?id=T15215022", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p26", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 26 }, { "id": "T15215023", "href": "https://app.finbar.com/go?id=T15215023", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p26", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 26 }, { "id": "P132644303", "href": "https://app.finbar.com/go?id=P132644303", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p140", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 140 }, { "id": "P132642854", "href": "https://app.finbar.com/go?id=P132642854", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p9", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 9 }, { "id": "P132642801", "href": "https://app.finbar.com/go?id=P132642801", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p3", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 3 }, { "id": "P132645276", "href": "https://app.finbar.com/go?id=P132645276", "label": "JIANGSU HENGRUI PHARMACEUT-A — Presentation (2025 Y), p31", "documentId": "D-146735402db3456ab9f35f081d4f5e2e", "page": 31 }, { "id": "P132644949", "href": "https://app.finbar.com/go?id=P132644949", "label": "JIANGSU HENGRUI PHARMACEUT-A — Presentation (2025 Y), p12", "documentId": "D-146735402db3456ab9f35f081d4f5e2e", "page": 12 }, { "id": "P132642877", "href": "https://app.finbar.com/go?id=P132642877", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p12", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 12 }, { "id": "T15215065", "href": "https://app.finbar.com/go?id=T15215065", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p140", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 140 }, { "id": "P132643769", "href": "https://app.finbar.com/go?id=P132643769", "label": "JIANGSU HENGRUI PHARMACEUT-A — Full financial report (2025 Y), p95", "documentId": "D-7921196b638c44a59f825d636b466135", "page": 95 } ] }